Asenapine side effects: oral hypoesthesia, sedation, weight

Asenapine, marketed as Saphris in sublingual form and Secuado as a transdermal patch, is one of the more unusual atypical antipsychotics available. The sublingual formulation exists because asenapine has poor oral bioavailability — swallowing it would render it nearly inactive. Holding the tablet under the tongue allows direct mucosal absorption. The patch was developed to bypass that requirement and offer once-daily, gut-independent dosing. Both delivery routes shape the side-effect experience in ways that few other antipsychotics share.

Oral hypoesthesia: the signature side effect

Within minutes of placing a Saphris tablet under the tongue, most patients experience numbness or tingling of the mouth and tongue — sometimes extending to the cheeks, lips, or throat. The medical term is oral hypoesthesia. It typically lasts an hour or two and resolves on its own. For some patients it is a mild, manageable curiosity; for others it is intolerable and a reason to switch.

Practical points:

• Do not eat or drink for at least 10 minutes after dissolving the tablet (the FDA labelling, available at Drugs@FDA, suggests longer is better)
• Allow the tablet to dissolve completely; do not chew or swallow it
• Do not split or crush the tablet
• The Secuado patch avoids the numb-mouth effect entirely

A small subset of patients develop more dramatic oropharyngeal swelling, which can cross into a hypersensitivity reaction. Any swelling beyond mild numbness — particularly with difficulty breathing or swallowing — needs urgent evaluation.

Sedation

Asenapine is moderately sedating, more than aripiprazole but less than olanzapine or quetiapine. The sublingual route gives a faster onset than most oral antipsychotics — patients often feel the drug within 30–60 minutes. Many take it at bedtime to leverage this. The Secuado patch produces steadier blood levels and somewhat less sedation, though this varies.

Weight and metabolic effects

Asenapine sits in the middle of the metabolic spectrum: more weight gain than aripiprazole, lurasidone, or ziprasidone, but less than olanzapine, clozapine, or quetiapine. Average gain in the first year is in the 2–4 kg range, though individual variation is significant. Effects on glucose and lipids are modest but warrant standard monitoring.

For practical strategies see our weight gain guide.

Movement effects

Asenapine produces dose-dependent EPS:

• Akathisia — common, particularly during titration
• Parkinsonism — tremor, stiffness, slowed movement; more at higher doses
• Acute dystonia — uncommon
• Tardive dyskinesia — possible with long-term use; risk lower than first-generation agents

See our EPS overview and tardive dyskinesia explainer.

Prolactin

Asenapine produces modest prolactin elevation — less than risperidone or paliperidone, more than aripiprazole. Symptomatic hyperprolactinemia is uncommon but possible.

Cardiovascular effects

Asenapine has modest QT-prolonging effects — comparable to or slightly greater than risperidone, less than ziprasidone. Caution is warranted with combinations of QT-prolonging drugs and in patients with cardiac risk factors. See QT prolongation. Orthostatic hypotension is also possible, particularly during titration.

The patch (Secuado)

Secuado is a once-daily transdermal patch in three strengths. Advantages:

• Bypasses the sublingual route and avoids oral numbness
• Steadier blood levels with less peak-related side effects
• Useful for patients who struggle with sublingual administration

The trade-offs include local skin reactions (redness, itching, occasional rash at the patch site — usually managed by rotating sites), the practical need to remember a daily change, and the constraint of avoiding heat sources directly on the patch (which can increase absorption).

Other reported effects

• Dizziness
• Increased appetite
• Constipation
• Nausea

Approved uses

• Schizophrenia (Saphris and Secuado, both adults; Saphris also for adolescents 12+)
• Acute manic and mixed episodes of bipolar I disorder (Saphris, both as monotherapy and as adjunctive therapy)
• Bipolar I maintenance (Saphris)

Boxed warnings

• Increased mortality in elderly patients with dementia-related psychosis
• Severe hypersensitivity reactions reported with the sublingual form

When to call the prescriber

• Mouth, throat, or facial swelling; difficulty breathing or swallowing
• Persistent oral discomfort beyond expected numbness
• Restlessness, tremor, stiffness, or unusual movements
• Significant weight gain
• Skin reactions to the patch
• Loss of menstrual periods, breast changes, or sexual side effects

Switching considerations

Patients who can't tolerate the oral numbness of Saphris often try Secuado first if asenapine is otherwise working. If asenapine itself is the issue, alternatives include any other atypical depending on the priority — weight, prolactin, sedation, or efficacy. Common moves include risperidone, paliperidone (both with similar EPS profile but no oral numbness), olanzapine (more sedating, more weight), or aripiprazole (more activating, less weight).

The bottom line

Asenapine occupies a small but useful niche — it can work for patients who haven't done well on more common alternatives, and the patch formulation is a genuine advantage for some. The signature numb-mouth effect is worth understanding before starting; the rest of the side-effect profile is comparable to other moderately sedating atypicals. As always, the trial belongs in the context of an honest conversation with a prescriber.

This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.